The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not ...

Roche (RHHBY) (RHHBF) has reiterated its plans to continue clinical trials for its anti-myostatin antibody emugrobart (GYM329/RO7204239) in obesity despite mid-stage trial setbacks for the candidate ...

Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle growth, raising questions about whether the molecule can preserve muscle in two ...

The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was hobbled by manufacturing concerns at a Novo Nordisk facility last year but ...

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA, ...

Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies for spinal muscular atrophy, Duchenne muscular dystrophy and Becker muscular ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

The Ironman In You project aims to raise awareness on muscular dystrophy It also aims to raise money for members of the Muscular Dystrophy Association of Singapore As of June 25, this project had ...

New York, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve), developed ...